According to the official WeChat account of Sanofi China, on November 1st, Sanofi announced that its first ROCK2 inhibitor, Besudil Mesylate Tablets (REZUROCK®), will be commercially launched by Sanofi China for the treatment of chronic graft-versus-host disease (cGVHD) patients aged 12 and above who do not respond adequately to glucocorticoids or other systemic therapies.
Sanofi said that it had reached an agreement with BK PHARMACEUTICALS and Yehui Pharmaceutical to withdraw Sanofi's exclusive right to develop and commercialize besudil mesylate tablets in Chinese Mainland. BK PHARMACEUTICALS and Yehui Pharmaceuticals previously signed an exclusive license agreement with KADMON CORPORATION, LLC (now a wholly-owned subsidiary of Sanofi) to obtain the aforementioned rights, which was also terminated.